

A research study to compare 2 antibacterial drugs, gatifloxacin with ciprofloxacin, for the treatment of dysentery in children

Submission date 15/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 18/01/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 13/03/2013	Condition category Digestive System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Vinh Ha

Contact details

Oxford University Clinical Research Unit

Hospital for Tropical Diseases

Ho Chi Minh City

Viet Nam

5

+84 8 9237954

vinhh@oucru.org

Additional identifiers

Protocol serial number

061330

Study information

Scientific Title

A randomised controlled trial of gatifloxacin versus ciprofloxacin for the treatment of bacillary dysentery in children

Acronym

EG

Study objectives

In 2004, The World Health Organization (WHO) organised a meeting of experts around the world and recommended that ciprofloxacin or other fluoroquinolones should be used to treat shigellosis in children as well as adults. However after being used for some years to treat shigellosis, the clinical response to ciprofloxacin treatment has decreased, strains of *Shigella dysenteriae* type 1 resistant to ciprofloxacin were also detected. This is why searching for alternative regimens is obviously needed. This study will compare the currently recommended WHO regimen with a newer, affordable and potentially more active fluoroquinolone, i.e., gatifloxacin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from Oxford Tropical Research Ethics Committee on the 20th June 2006 (ref: OXTREC 010-06).

Study design

Open-label randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Shigella dysentery

Interventions

Patients are randomised to:

1. Ciprofloxacin 15 mg/kg body weight taken orally every 12 hours for a total of 6 doses in 3 days, or
2. Gatifloxacin 10 mg/kg body weight taken orally every 24 hours for a total of 3 doses in 3 days

Follow-up will occur for 7 - 10 days after discharge from the hospital.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Ciprofloxacin, gatifloxacin

Primary outcome(s)

Failure of treatment:

1. Persistent fever at Day 5
2. Failure to clear completely the admission symptoms at Day 5
3. Stool culture positive at Day 3 of treatment
4. Need for rescue treatment with ceftriaxone
5. The development on treatment of any complication

Key secondary outcome(s)

1. Fever clearance time: from the start of treatment until axillary temperature falls to 37.5°C and remains at or below this value for greater than 48 hours
2. Bloody diarrhoea clearance time: the time to the last stool containing visible blood passed
3. Diarrhoea clearance time: the time to the first formed stool
4. Bacterial clearance time: time to the last positive stools culture for Shigella

Completion date

30/03/2009

Eligibility

Key inclusion criteria

1. Patients aged 0 - 14, either sex
2. Symptomatic uncomplicated dysentery
3. Gives consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

0 years

Upper age limit

14 years

Sex

All

Key exclusion criteria

No consent given.

Date of first enrolment

01/06/2006

Date of final enrolment

30/03/2009

Locations

Countries of recruitment

Viet Nam

Study participating centre

Oxford University Clinical Research Unit

Ho Chi Minh City

Viet Nam

5

Sponsor information

Organisation

University of Oxford (UK)

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

Charity

Funder Name

The Wellcome Trust (UK) (grant ref: 061330)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/12/2009		Yes	No
Results article	results	01/08/2011		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes